Blue Water Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
October 20, 2023 at 10:13 pm
Share
Blue Water Biotech, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 6.87 million compared to USD 4.26 million a year ago. Basic loss per share from continuing operations was USD 0.43 compared to USD 0.36 a year ago.
For the six months, net loss was USD 9.71 million compared to USD 6.34 million a year ago. Basic loss per share from continuing operations was USD 0.61 compared to USD 0.7 a year ago.
Onconetix, Inc. is a commercial stage biotechnology company. It is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a next generation protein-based blood test that can be done with the same sample as a patientâs regular PSA test. Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable cancer management at all stages of disease progression.